Pharmaceuticals, Biotechnology and Life Sciences
– 86% overall survival (OS) observed at 9 months; standard of care benchmark is ~47% – – 53% progression-free survival…
Program will include an update on the Company’s lead asset, lanifibranor, ahead of anticipated Phase 3 NATiV3 topline results in…
Breakthrough Therapies and Life Sciences Leadership Take Center Stage October 1–2 in Newport BeachLOS ANGELES, Sept. 24, 2025 (GLOBE NEWSWIRE)…
H1 2025 results Activity and profitability H1 revenue: €387.8 million, down 5.4% at CER1 and on a like-for-like basis2, mainly…
RESULTS FOR THE FIRST SEMESTER OF FISCAL YEAR 2025 Revenue up 10% to €80.7 million Proprietary products account for 36%…
Press release – No. 14 / 2025 Zealand Pharma appoints Rachel James-Owens as Vice President, Corporate Communications & Media Relations…
CHASKA, Minn., Sept. 23, 2025 (GLOBE NEWSWIRE) — Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”) a fully integrated contract development and…
CAMBRIDGE, Mass., Sept. 23, 2025 (GLOBE NEWSWIRE) — Biogen Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug…
CARLSBAD, Calif., Sept. 23, 2025 (GLOBE NEWSWIRE) — Natural Alternatives International, Inc. (“NAI”) (Nasdaq: NAII), a leading formulator, manufacturer, and…
OSE Immunotherapeutics acknowledges the decision of the Nantes Commercial Court NANTES, France – September 23, 2025, 10:30 p.m. CET –…